JinJuan Yao
A5083424175- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Single-cell and spatial transcriptomics
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Renal cell carcinoma treatment
- Ubiquitin and proteasome pathways
- Biosimilars and Bioanalytical Methods
- Neurofibromatosis and Schwannoma Cases
- Protein Degradation and Inhibitors
- Integrated Circuits and Semiconductor Failure Analysis
- Cutaneous lymphoproliferative disorders research
Memorial Sloan Kettering Cancer Center
2011-2024
North China University of Science and Technology Affiliated Hospital
2023
Cold Spring Harbor Laboratory
2011
SUNY Downstate Health Sciences University
2011
Kings County Hospital Center
2010
State University of New York
2010
Abstract The oncogenetic events that transform chronic myeloproliferative neoplasms (MPN) to acute myeloid leukemias (AML) are not well characterized. We investigated the role of several genes implicated in leukemic transformation by mutational analysis 63 patients with AML secondary a preexisting MPN (sAML). Frequent mutations were identified TET2 (26.3%), ASXL1 (19.3%), IDH1 (9.5%), and JAK2 (36.8%) sAML, all possible combinations these also observed. Analysis 14 for which paired samples...
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis cfDNA Examine Somatic Status), an NGS assay for detection very low frequency alterations in 129 genes. Analytical validation demonstrated 92% sensitivity de-novo mutation calling down 0.5% allele and 99% a priori profiling. To evaluate the performance MSK-ACCESS, report results 681 prospective...
BACKGROUND. Refractory CMV viremia and disease are associated with significant morbidity mortality in recipients of hematopoietic stem cell transplant (HCT).
Abstract Genomic profiling of hematologic malignancies has augmented our understanding variants that contribute to disease pathogenesis and supported development prognostic models inform management in the clinic. Tumor only sequencing assays are limited their ability identify definitive somatic variants, which can lead ambiguity clinical reporting patient management. Here, we describe MSK-IMPACT Heme cohort, a comprehensive data set alterations from paired tumor normal DNA using...
Context Touch preparations (TP) of core needle biopsies (CNBs) are used at some institutions for on-site assessment CNB adequacy. In our clinical practice, we have encountered instances in which TPs resulted substantial depletion cellularity. Objective To examine the effect increasingly vigorous on cellularity and DNA content CNBs. Design Ex vivo CNBs (n = 56) were performed resected lung kidney tumor specimens. For each specimen, quadruplicate nontumor tissue subjected to 1 4 TP methods:...
Desmoplastic small round cell tumor (DSRCT) is characterized by the t(11;22)(p13;q12) translocation, which fuses transcriptional regulatory domain of EWSR1 with DNA-binding WT1, resulting in oncogenic EWSR1-WT1 fusion protein. The paucity DSRCT disease models has hampered preclinical therapeutic studies on this aggressive cancer. Here, we developed and mined expression profiles to identify genetic vulnerabilities that could be leveraged for new therapies. We describe four lines one...
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events challenging but greatly facilitated by matched analysis tumor:normal pairs samples. contrast to solid tumors, malignancies conventional sources normal control material (peripheral blood, buccal swabs, saliva) could be highly involved neoplastic process,...
Myeloid ELF1-like factor (MEF), also known as ELF4, is a member of the ETS family transcription factors which expressed in hematopoietic cells. MEF-deficient mice have defects natural killer cell and T development, suggesting role for MEF regulating innate immunity. functions myeloid cells, where it can transactivate target genes. To identify genes "myeloid" environment, we created an inducible expression system used oligonucleotide microarrays to examine transcript profile HEL cells after...
MEF is an ETS-related transcription factor with strong transcriptional activating activity that affects hematopoietic stem cell behavior and required for normal NK T-cell development. The (also known as ELF4) gene repressed by several leukemia-associated fusion proteins (PML-retinoic acid receptor alpha AML1-ETO), but it also activated retroviral insertion in cancer models. We have previously shown cyclin A-dependent phosphorylation of largely restricts its to the G(1) phase cycle; we now...
Adult T-cell leukemia/lymphoma (ATLL) is caused by the HTLV-1 virus, endemic to Japan and Caribbean, likely derived from cells with T-regulatory phenotype. The malignant express IL2 receptor α (CD25), majority transcription factor Forkhead box P3 (Foxp3), in addition markers. Occasional cases CD30. Whereas Japanese are predominantly of acute chronic leukemic types, less well-studied Caribbean more often lymphomatous. We performed immunohistochemical analysis for CD25, Foxp3, CD30 on samples...
Context.— The increasing use of large panel next-generation sequencing technologies in clinical settings has facilitated the identification pan-cancer biomarkers, which can be diagnostic, prognostic, predictive, or most importantly, actionable. Objective.— To discuss recently approved and emerging multihistology biomarkers as well testing methodologies. Data Sources.— US Food Drug Administration approval documents, National Comprehensive Cancer Network guidelines, literature, authors' own...